Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Asset Writedowns and Impairment (2019 - 2024)

Lifecore Biomedical, Inc. \De\ has reported Asset Writedowns and Impairment over the past 8 years, most recently at -$1.4 million for Q2 2024.

  • Quarterly results put Asset Writedowns and Impairment at -$1.4 million for Q2 2024, down 240.2% from a year ago — trailing twelve months through May 2024 was $2.0 million (down 95.93% YoY), and the annual figure for FY2023 was $1.3 million, down 98.34%.
  • Asset Writedowns and Impairment for Q2 2024 was -$1.4 million at Lifecore Biomedical, Inc. \De\, down from $1.4 million in the prior quarter.
  • Over the last five years, Asset Writedowns and Impairment for LFCR hit a ceiling of $46.1 million in Q2 2022 and a floor of -$1.4 million in Q2 2024.
  • Median Asset Writedowns and Impairment over the past 5 years was $1.0 million (2022), compared with a mean of $7.2 million.
  • Biggest five-year swings in Asset Writedowns and Impairment: soared 47656.72% in 2021 and later tumbled 240.2% in 2024.
  • Lifecore Biomedical, Inc. \De\'s Asset Writedowns and Impairment stood at $67000.0 in 2020, then soared by 47656.72% to $32.0 million in 2021, then tumbled by 96.87% to $1.0 million in 2022, then changed by 0.0% to $1.0 million in 2023, then tumbled by 240.2% to -$1.4 million in 2024.
  • The last three reported values for Asset Writedowns and Impairment were -$1.4 million (Q2 2024), $1.4 million (Q1 2024), and $1.0 million (Q2 2023) per Business Quant data.